1. Structural Biology and Molecular Biophysics

Conserved allosteric inhibition mechanism in SLC1 transporters

  1. Yang Dong
  2. Jiali Wang
  3. Rachel-Ann Garibsingh
  4. Keino Hutchinson
  5. Yueyue Shi
  6. Gilad Eisenberg
  7. Xiaozhen Yu
  8. Avner Schlessinger  Is a corresponding author
  9. Christof Grewer  Is a corresponding author
  1. Binghamton University, United States
  2. Icahn School of Medicine at Mount Sinai, United States
https://doi.org/10.7554/eLife.83464
Share this article
Cite this article
  1. Yang Dong
  2. Jiali Wang
  3. Rachel-Ann Garibsingh
  4. Keino Hutchinson
  5. Yueyue Shi
  6. Gilad Eisenberg
  7. Xiaozhen Yu
  8. Avner Schlessinger
  9. Christof Grewer
(2023)
Conserved allosteric inhibition mechanism in SLC1 transporters
eLife 12:e83464.
https://doi.org/10.7554/eLife.83464
  2. Download BibTeX
  3. Download .RIS

Abstract

Excitatory Amino Acid Transporter 1 (EAAT1) is a plasma-membrane glutamate transporter belonging to the SLC1 family of solute carriers . It plays a key role in neurotransmitter transport and contributes to the regulation of the extracellular glutamate concentration in the mammalian brain. The structure of EAAT1 was determined in complex with UCPH-101, a highly potent and non-competitive inhibitor of EAAT1. Alanine Serine Cysteine Transporter 2 (ASCT2) is a neutral amino acid transporter, which regulates pools of amino acids such as glutamine, serine and alanine between intracellular and extracellular compartments in a Na+ dependent manner. ASCT2 also belongs to the SLC1 family and shares 58% sequence similarity with EAAT1. However, allosteric modulation of ASCT2 via non-competitive inhibitors is unknown. Here we explore the UCPH-101 inhibitory mechanisms of EAAT1 and ASCT2 by using rapid kinetic experiments. Our results show that UCPH-101 slows substrate translocation rather than substrate or Na+ binding, confirming a non-competitive inhibitory mechanism, but only partially inhibits wild-type ASCT2 with relatively low affinity. Guided by computational modeling using ligand docking and molecular dynamics (MD) simulations, we selected two residues involved in UCPH-101/EAAT1 interaction, which were mutated in ASCT2 (F136Y, I237M, F136Y/I237M) in the corresponding positions. We show that in the F136Y/I237M double mutant transporter, 100% of the inhibitory effect of UCPH-101 on anion current could be restored, and the apparent affinity was increased (Ki = 9.3 mM), much closer to the EAAT1 value of 0.6 mM. Finally, we identify a novel non-competitive ASCT2 inhibitor, identified through virtual screening and experimental testing against the allosteric site, further supporting its localization. Together, these data indicate that the mechanism of allosteric modulation is conserved between EAAT1 and ASCT2. Due to the difference in binding site residues between ASCT2 and EAAT1, these results raise the possibility that more potent, and potentially selective inhibitors can be designed that target the ASCT2 allosteric binding site.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting file. The original, source data files were uploaded as spreadsheets for figures 3-10, Table 1, and Figure supplements 3,4,5,6 and 9. The MD parametrization files for UCPH-101 are also included.

Article and author information

Author details

  1. Yang Dong

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Jiali Wang

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9520-8140

  3. Rachel-Ann Garibsingh

    Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Ney York, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Keino Hutchinson

    Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Yueyue Shi

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Gilad Eisenberg

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Xiaozhen Yu

    Department of Chemistry, Binghamton University, Binghamton, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Avner Schlessinger

    Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    For correspondence
    avner.schlessinger@mssm.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4007-7814

  9. Christof Grewer

    Department of Chemistry, Binghamton University, Binghamton, United States
    For correspondence
    cgrewer@binghamton.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8342-9878

Funding

National Institutes of Health (R01 GM108911)

  • Avner Schlessinger
  • Christof Grewer

National Institutes of Health (T32 CA078207)

  • Rachel-Ann Garibsingh

National Institutes of Health (R15 GM135843-01)

  • Christof Grewer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Randy B Stockbridge, University of Michigan, United States

Version history

  1. Received: September 14, 2022
  2. Preprint posted: September 22, 2022 (view preprint)
  3. Accepted: February 27, 2023
  4. Accepted Manuscript published: March 1, 2023 (version 1)
  5. Accepted Manuscript updated: March 1, 2023 (version 2)
  6. Version of Record published: March 15, 2023 (version 3)

Copyright

© 2023, Dong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,200
    views
  • 208
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yang Dong
  2. Jiali Wang
  3. Rachel-Ann Garibsingh
  4. Keino Hutchinson
  5. Yueyue Shi
  6. Gilad Eisenberg
  7. Xiaozhen Yu
  8. Avner Schlessinger
  9. Christof Grewer
(2023)
Conserved allosteric inhibition mechanism in SLC1 transporters
eLife 12:e83464.
https://doi.org/10.7554/eLife.83464

Share this article

https://doi.org/10.7554/eLife.83464

Categories and tags

Research organisms

Further reading

    1. Structural Biology and Molecular Biophysics

    Dependence of nucleosome mechanical stability on DNA mismatches

    Thuy TM Ngo, Bailey Liu ... Taekjip Ha
    Research Article

    The organization of nucleosomes into chromatin and their accessibility are shaped by local DNA mechanics. Conversely, nucleosome positions shape genetic variations, which may originate from mismatches during replication and chemical modification of DNA. To investigate how DNA mismatches affect the mechanical stability and the exposure of nucleosomal DNA, we used an optical trap combined with single-molecule FRET and a single-molecule FRET cyclization assay. We found that a single base-pair C-C mismatch enhances DNA bendability and nucleosome mechanical stability for the 601-nucleosome positioning sequence. An increase in force required for DNA unwrapping from the histone core is observed for single base-pair C-C mismatches placed at three tested positions: at the inner turn, at the outer turn, or at the junction of the inner and outer turn of the nucleosome. The results support a model where nucleosomal DNA accessibility is reduced by mismatches, potentially explaining the preferred accumulation of single-nucleotide substitutions in the nucleosome core and serving as the source of genetic variation during evolution and cancer progression. Mechanical stability of an intact nucleosome, that is mismatch-free, is also dependent on the species as we find that yeast nucleosomes are mechanically less stable and more symmetrical in the outer turn unwrapping compared to Xenopus nucleosomes.

    1. Cell Biology
    2. Structural Biology and Molecular Biophysics

    PURA syndrome-causing mutations impair PUR-domain integrity and affect P-body association

    Marcel Proske, Robert Janowski ... Dierk Niessing
    Research Article

    Mutations in the human PURA gene cause the neurodevelopmental PURA syndrome. In contrast to several other monogenetic disorders, almost all reported mutations in this nucleic acid-binding protein result in the full disease penetrance. In this study, we observed that patient mutations across PURA impair its previously reported co-localization with processing bodies. These mutations either destroyed the folding integrity, RNA binding, or dimerization of PURA. We also solved the crystal structures of the N- and C-terminal PUR domains of human PURA and combined them with molecular dynamics simulations and nuclear magnetic resonance measurements. The observed unusually high dynamics and structural promiscuity of PURA indicated that this protein is particularly susceptible to mutations impairing its structural integrity. It offers an explanation why even conservative mutations across PURA result in the full penetrance of symptoms in patients with PURA syndrome.

    1. Microbiology and Infectious Disease
    2. Structural Biology and Molecular Biophysics

    Molecular mechanism of complement inhibition by the trypanosome receptor ISG65

    Alexander D Cook, Mark Carrington, Matthew K Higgins
    Research Article

    African trypanosomes replicate within infected mammals where they are exposed to the complement system. This system centres around complement C3, which is present in a soluble form in serum but becomes covalently deposited onto the surfaces of pathogens after proteolytic cleavage to C3b. Membrane-associated C3b triggers different complement-mediated effectors which promote pathogen clearance. To counter complement-mediated clearance, African trypanosomes have a cell surface receptor, ISG65, which binds to C3b and which decreases the rate of trypanosome clearance in an infection model. However, the mechanism by which ISG65 reduces C3b function has not been determined. We reveal through cryogenic electron microscopy that ISG65 has two distinct binding sites for C3b, only one of which is available in C3 and C3d. We show that ISG65 does not block the formation of C3b or the function of the C3 convertase which catalyses the surface deposition of C3b. However, we show that ISG65 forms a specific conjugate with C3b, perhaps acting as a decoy. ISG65 also occludes the binding sites for complement receptors 2 and 3, which may disrupt recruitment of immune cells, including B cells, phagocytes, and granulocytes. This suggests that ISG65 protects trypanosomes by combining multiple approaches to dampen the complement cascade.